Transporter‐Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug–Drug Interactions of Montelukast
Authors:
- 18 November 2016
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 101 (3) , 406-415
Abstract
Montelukast, a leukotriene receptor antagonist commonly prescribed for treatment of asthma, is primarily metabolized by cytochrome P450 (CYP)2C8, and has been suggested as a probe substrate for investigating CYP2C8 activity in vivo. We evaluated the quantitative role of hepatic uptake transport in its pharmacokinetics and drug–drug interactions (DDIs). Montelukast was characterized with significant active uptake in human hepatocytes, and showed affinity towards organic anion transporting polypeptides (OATPs) in transfected cell systems. Single-dose rifampicin, an OATP inhibitor, decreased montelukast clearance in rats and monkeys. Clinical DDIs of montelukast were evaluated using physiologically based pharmacokinetic modeling; and simulation of the interactions with gemfibrozil–CYP2C8 and OATP1B1/1B3 inhibitor, clarithromycin–CYP3A and OATP1B1/1B3 inhibitor, and itraconazole–CYP3A inhibitor, implicated OATPs-CYP2C8-CYP2C8 interplay as the primary determinant of montelukast pharmacokinetics. In conclusion, hepatic uptake plays a key role in the pharmacokinetics of montelukast, which should be taken into account when interpreting clinical interactions.Keywords
This publication has 46 references indexed in Scilit:
- Role of Cytochrome P450 2C8 in Drug Metabolism and InteractionsPharmacological Reviews, 2016
- Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)Pharmaceutical Research, 2015
- Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorptionBiopharmaceutics & Drug Disposition, 2013
- Evaluation of CYP2C8 Inhibition In Vitro: Utility of Montelukast as a Selective CYP2C8 Probe SubstrateDrug Metabolism and Disposition, 2011
- Reevaluation of the Microsomal Metabolism of Montelukast: Major Contribution by CYP2C8 at Clinically Relevant ConcentrationsDrug Metabolism and Disposition, 2011
- Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of MontelukastClinical Pharmacology & Therapeutics, 2010
- GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONSDrug Metabolism and Disposition, 2006
- A review of montelukast in the treatment of asthma and allergic rhinitisExpert Opinion on Pharmacotherapy, 2004
- Montelukast, a Once-Daily Leukotriene Receptor Antagonist, in the Treatment of Chronic AsthmaA Multicenter, Randomized, Double-blind TrialArchives of internal medicine (1960), 1998
- Pharmacokinetics, Bioavailability, and Safety of Montelukast Sodium (MK-0476) in Healthy Males and FemalesPharmaceutical Research, 1996